Goldfinch's Product Engine integrates genetics and kidney biology to identify new therapeutic targets for progressive kidney disease, with a focus on Focal Segmental Glomerulosclerosis and Diabetic Nephropathy. Their precision medicine approach allows them to pioneer the discovery, development, and commercialization of kidney disease treatments by identifying patient subsets most likely to respond to their treatment. Goldfinch has a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet medical need.